NIAID SBIR-Technology Transfer Direct Phase II (R44)
The summary for the NIAID SBIR-Technology Transfer Direct Phase II (R44) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
NIAID SBIR-Technology Transfer Direct Phase II (R44): The goal of this Funding Opportunity Announcement (FOA) is to move commercially-viable vaccines and products for treatment and prevention of diseases relevant to NIAID's mission from NIAID intramural research laboratories into the marketplace. This FOA solicits Small Business Innovation Research (SBIR) grant applications from Small Business Concerns (SBCs) for projects that incorporate the appropriate research expertise (company, NIAID Intramural or external collaborators/consortiums) to further develop and commercialize such inventions. The Direct-to-Phase II grant mechanism is intended to facilitate SBIR-type research and development, to expand research and development opportunities for applicant SBCs, and to enhance the pace of technology development and commercialization.
Federal Grant Title: | NIAID SBIR-Technology Transfer Direct Phase II (R44) |
Federal Agency Name: | National Institutes of Health |
Grant Categories: | Health |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | RFA-AI-16-009 |
Type of Funding: | Grant |
CFDA Numbers: | 93.855, 93.856 |
CFDA Descriptions: | Allergy and Infectious Diseases Research; Microbiology and Infectious Diseases Research |
Current Application Deadline: | Jun 23, 2016 |
Original Application Deadline: | Jun 23, 2016 |
Posted Date: | Feb 17, 2016 |
Creation Date: | Feb 18, 2016 |
Archive Date: | Jul 24, 2016 |
Total Program Funding: | $2,000,000 |
Maximum Federal Grant Award: | none |
Minimum Federal Grant Award: | none |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
- Applicants Eligible for this Grant
- Small businesses
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
- Link to Full Grant Announcement
- http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-16-009.html
- Grant Announcement Contact
- NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
National Institutes of Health 301-496-3405 - Similar Government Grants
- • Global Infectious Disease Research Training Program (D43 Clinical Trial Optional)
- • Immunobiology of Xenotransplantation (U19 Clinical Trial Not Allowed)
- • Partnerships for the Development of Tools to Advance Therapeutic Discovery for Select Anti...
- • Immunobiology of Xenotransplantation (U01 Clinical Trial Not Allowed)
- • Limited Interaction Targeted Epidemiology: Epidemiology of Transmission and Treatment of H...
- • Center for HIV/AIDS Vaccine Immunology (CHAVI)
- • Genomics of Transplantation Cooperative Research Program
- • Asthma and Allergic Diseases Cooperative Research Centers
- More Grants from the National Institutes of Health
- • The NCI Worta McCaskill-Stevens Career Development Award for Community Oncology and Preven...
- • Interventions to Reduce Sleep Health Disparities (R01 - Clinical Trials Optional)
- • Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Tri...
- • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...
- • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...